Understanding Factor V Deficiency (Parahemophilia, Owren's Disease): Find information on diagnosis, clinical features, and medical coding for Factor V deficiency. This resource covers healthcare considerations, laboratory testing, and treatment options for patients with inherited bleeding disorders. Learn about Factor V Leiden mutation testing, differential diagnosis, and ICD-10 codes related to Factor V deficiency for accurate clinical documentation and billing.
Also known as
Factor V deficiency
Inherited deficiency of coagulation factor V.
Hereditary factor VIII and factor IX deficiencies
Includes hemophilia A, B, and other related bleeding disorders.
Coagulation defects
Encompasses various inherited and acquired bleeding disorders.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the Factor V deficiency acquired or congenital?
When to use each related code
| Description |
|---|
| Blood doesn't clot normally, causing easy bleeding. |
| Combined deficiency of factors V and VIII, rare bleeding disorder. |
| Blood clots too easily, increased risk of DVT and PE. |
Coding F5 deficiency without specifying acquired vs. hereditary (e.g., F5 Leiden) impacts severity and treatment.
Discrepancies between clinical notes and coded diagnosis (e.g., parahemophilia vs. Owren's) can lead to audit issues.
Failing to code related manifestations (e.g., DVT, pulmonary embolism) underreports disease severity and resource utilization.
Q: What are the most effective diagnostic strategies for confirming Factor V Leiden and differentiating it from inherited Factor V deficiency?
A: Differentiating Factor V Leiden, a genetic mutation causing activated protein C resistance, from inherited Factor V deficiency, a bleeding disorder, requires a multi-pronged approach. While both affect Factor V, their clinical presentations differ significantly. Begin with a thorough patient history, including family history of bleeding or thrombotic events. Prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) can suggest Factor V deficiency, but are usually normal in Factor V Leiden. A key diagnostic test is the Factor V activity assay. Low levels confirm Factor V deficiency, while normal or near-normal levels suggest Factor V Leiden or other causes. Genetic testing for the Factor V Leiden mutation can definitively confirm that diagnosis. Consider implementing a stepwise diagnostic algorithm starting with coagulation screening, followed by Factor V activity assay, and finally genetic testing to provide accurate diagnosis and guide appropriate management. Explore how specific laboratory assays can help pinpoint the underlying cause of coagulopathy.
Q: How does managing acute bleeding episodes in a patient with known Factor V deficiency differ from standard hemophilia A or B management?
A: Managing acute bleeding in Factor V deficiency differs from hemophilia A or B, primarily in the choice of replacement therapy. Unlike hemophilia, where factor VIII or IX concentrates are used, Factor V deficiency requires fresh frozen plasma (FFP) or, ideally, a purified Factor V concentrate if available. FFP contains all coagulation factors, effectively replenishing Factor V. The dose and frequency of FFP depend on the severity and location of the bleeding. While recombinant Factor V concentrates are not widely accessible, they offer advantages over FFP, including reduced risk of volume overload and infectious disease transmission. Consider implementing a treatment protocol based on patient-specific factors like bleeding severity and access to specialized therapies. Learn more about the optimal utilization of FFP and the potential benefits of Factor V concentrates in managing acute bleeding episodes.
Patient presents with [chief complaint related to bleeding e.g., easy bruising, prolonged bleeding after minor injury, epistaxis, menorrhagia]. Review of systems reveals [positive findings related to bleeding or family history, e.g., hematuria, gingival bleeding, family history of bleeding disorder]. Physical exam findings include [relevant findings e.g., ecchymoses, petechiae, active bleeding]. Given the clinical presentation, Factor V deficiency, also known as parahemophilia or Owren's disease, is suspected. Differential diagnosis includes other inherited bleeding disorders such as hemophilia A, hemophilia B, von Willebrand disease, and other coagulation factor deficiencies. Coagulation studies including Factor V assay were ordered to confirm the diagnosis and assess the severity of the deficiency. Preliminary laboratory results indicate [initial findings, e.g., prolonged PT, normal aPTT]. Further testing may include genetic testing for Factor V Leiden mutation to differentiate from activated protein C resistance. Diagnosis of Factor V deficiency will be confirmed based on reduced Factor V activity levels. Management plan will be determined based on the severity of the deficiency and bleeding manifestations. Treatment options for acute bleeding episodes may include fresh frozen plasma, Factor V concentrate, or recombinant Factor V. Prophylactic treatment may be considered in patients with a history of severe bleeding. Patient education on bleeding precautions, signs and symptoms of bleeding, and the importance of regular follow-up with a hematologist will be provided. ICD-10 code D68.4 (Factor V deficiency) is documented. Follow-up appointment scheduled for [date] to discuss complete coagulation panel results and establish a long-term management plan.